波多野结衣办公室双飞_制服 丝袜 综合 日韩 欧美_网站永久看片免费_欧美一级片在线免费观看_免费视频91蜜桃_精产国品一区二区三区_97超碰免费在线观看_欧美做受喷浆在线观看_国产熟妇搡bbbb搡bbbb_麻豆精品国产传媒

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Innovation

Dedication, team work boost China's COVID-19 research

Xinhua | Updated: 2022-03-29 14:33
Share
Share - WeChat
Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. [Photo provided to chinadaily.com.cn]

BEIJING -- Many clinicians have referred to a COVID-19 drug developed by Zhang Linqi as a "miracle medicine" after seeing their patients' lasting fever symptoms diminish quickly following an injection of the drug.

A virologist at China's Tsinghua University, Zhang led his team to create a cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which cut hospitalizations and deaths by 80 percent in human trials and appears to work well against all existing variants.

It took just 18 months for the Chinese drug to be developed and receive regulatory approval.

"In less than two years, we finished a job that would otherwise take at least 10 years," Zhang said.

His latest research uses a deep learning approach to help his team obtain antibodies that can neutralize the coronavirus and its variants at a faster pace.

Anti-COVID-19 research results from Chinese institutes, universities and enterprises have been published in international academic journals every two or three days since January. Chinese scientists are contributing their wisdom, experience and painstaking efforts to enhance the human capacity to cope with the deadly virus.

While the Academy of Military Medical Sciences presented an mRNA COVID-19 antibody that provided lasting immunity in mice, Fudan University created an adenovirus vaccine candidate designed to give dual protection against both COVID-19 and influenza viruses.

Researchers at the Chinese Academy of Sciences (CAS), China's top academic institute, are working on an inhalable antibody with low cost and large-scale production advantages, while pharmaceutical companies in Shanghai and Suzhou have commenced global trials of a co-developed oral drug for moderate and severe COVID-19 cases.

Speaking to press at the fifth session of the 13th National People's Congress earlier in March, Minister of Science and Technology Wang Zhigang said that China has had fruitful beginning to its development of COVID-19 vaccines and drugs, with several candidates being granted market approval or undergoing clinical trials.

"The more tools to tackle COVID-19 that science and technology can provide, the better our anti-pandemic measures can become," the minister said.

None of this progress has come easily. China's impressive pace of medical research is the result of the long-term hard work of Chinese scientists.

Wang Qihui is a CAS virologist. Since January 2020, when Wang first volunteered to work on COVID-19, she has been racing against the clock to find ways to defeat the virus.

Tasked with finding effective antibodies in a short time, Wang led her team to conduct experiments day and night. She once stayed in her laboratory for two weeks, sometimes forgetting food and sleep.

Five months after the initial outbreak of the novel coronavirus, her team announced that JS016, a COVID-19-neutralizing antibody that they had developed, could be administered to healthy people in clinical trials. In November last year, the antibody was granted emergency-use authorization in 15 countries, including the United States and several European countries.

Lots of sacrifices were made in this process. Right before the results of the COVID-19 antibody study came out, Wang Qihui experienced neurological deafness because of high stress, which led to temporary hearing loss in her left ear.

She was hospitalized for five days after a doctor warned her that, in the absence of timely treatment, she could develop permanently impaired hearing.

The scientist has since recovered and is determined to make greater contribution to the fight against the pandemic. She has resumed her COVID-19 research, working to develop a nasal spray antibody drug and an mRNA vaccine.

Wang Qihui attributes her achievements largely to her previous experience in the field of viral infectious diseases, such as Middle East Respiratory Syndrome (MERS) and the Zika virus.

Zhang Linqi and his team, like Wang, have used their determination and wealth of experience in responding to new pathogens to deal with the pandemic.

Zhang has devoted 30 years to the study of HIV-1 pathogenesis and vaccine development, and to emerging and re-emerging human viral pathogens such as MERS, Ebola and the Zika virus.

"The development of a treatment drug and a vaccine sounded lighting fast, even to me, but it benefited from years of research on antibody drugs and HIV vaccine development," Zhang said when asked how the COVID-19 antibody drug he developed was created so quickly.

Inspired by the "AIDS cocktail," a combination treatment of three or four different medicines for people with HIV/AIDS, Zhang and his team selected 206 monoclonal antibodies and whittled the number down to two, creating their COVID-19 cocktail therapy.

It has demonstrated an improved performance in resisting virus mutations and maintained longer activity in the human body compared to similar therapies consisting of only one antibody.

Xiamen University, which has also accumulated significant experience in vaccine development, is a major research force in the fight against COVID-19. It was also one of the first institutions to receive global virus research donations.

Emerging technologies are involved in COVID-19 research. Tech giant Baidu has licensed its mRNA sequencing algorithm to French vaccine maker Sanofi for use in the design of COVID-19 vaccines and therapeutic products. According to the Chinese company, the algorithm can accelerate the research.

Zhang also stressed that interdisciplinary collaboration is very important in his work. He collaborated with Tsinghua biologists to decipher the structure of the virus, and with Shenzhen clinicians to isolate monoclonal antibodies in convalescent patients. These partnerships accelerated the development of China's first COVID-19 antibody drug.

"Scientific research is to explore the unknown in blind zones. We scientists not only need strong hearts and big brains, but also partners to support us. Even if we fail, we are not alone, as there are many people supporting us," Zhang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
波多野结衣办公室双飞_制服 丝袜 综合 日韩 欧美_网站永久看片免费_欧美一级片在线免费观看_免费视频91蜜桃_精产国品一区二区三区_97超碰免费在线观看_欧美做受喷浆在线观看_国产熟妇搡bbbb搡bbbb_麻豆精品国产传媒
国产一区二区福利| 在线观看亚洲专区| 日韩精品一区在线| 日韩电影免费在线观看网站| 怡红院一区二区| 91精品国产综合久久福利软件| 亚洲国产婷婷综合在线精品| 美女流白浆视频| 在线播放欧美女士性生活| 亚洲18色成人| 国产精品无码网站| 欧美成人一区二区三区在线观看| 日韩国产欧美在线播放| 国产夫妻性爱视频| 精品成人免费观看| 国产乱码精品一品二品| 婷婷激情四射网| 18涩涩午夜精品.www| 91色porny| 欧美精品成人一区二区三区四区| 亚洲成人一区二区| 国产偷人妻精品一区| 欧美精品一区男女天堂| 国产乱妇无码大片在线观看| 日韩欧美国产成人精品免费| 亚洲情趣在线观看| 男女性杂交内射妇女bbwxz| 无码人妻丰满熟妇啪啪网站| 欧美日韩国产一二三| 日本美女视频一区二区| 亚洲色图 激情小说| 国产精品久久久久久久久快鸭| 99riav久久精品riav| 欧美高清一级片在线| 美日韩一区二区三区| 永久免费未视频| 亚洲精品成人精品456| 岛国精品资源网站| 久久久精品蜜桃| 91在线播放网址| 欧美一级国产精品| 国产精品99久久久久| 欧美亚洲一区二区三区四区| 日韩成人免费在线| 日韩一卡二卡在线观看| 亚洲精品日产精品乱码不卡| 成人免费无码大片a毛片| 国产日韩欧美高清在线| 91影院在线观看| 日韩欧美国产精品一区| 高清国产一区二区| 777午夜精品视频在线播放| 极品销魂美女一区二区三区| 色一区在线观看| 秋霞电影网一区二区| 中国一级片在线观看| 亚洲高清久久久| 美国精品一区二区| 亚洲二区视频在线| 999福利视频| 亚洲国产美女搞黄色| 亚洲色图日韩精品| 亚洲福中文字幕伊人影院| 在线观看日本中文字幕| 亚洲欧美另类小说视频| 制服 丝袜 综合 日韩 欧美| 亚洲激情在线激情| 超碰人人干人人| 亚洲高清不卡在线观看| 日韩免费av一区| 石原莉奈在线亚洲二区| 色哟哟国产精品免费观看| 老司机一区二区| 欧美色大人视频| 国产成人综合网| 日韩欧美精品在线视频| 99国产欧美另类久久久精品| 久久综合久久综合九色| 在线精品视频播放| 国产精品国产三级国产专播品爱网| 懂色av粉嫩av蜜乳av| 亚洲女爱视频在线| 91无套直看片红桃在线观看| 日韩精彩视频在线观看| 在线观看视频91| 国产成人av一区二区三区在线| 日韩精品一区二区三区蜜臀 | 亚洲综合一二三区| 一级性生活免费视频| 免费看日韩a级影片| 欧美三级视频在线| 成人app在线| 国产丝袜欧美中文另类| 在线观看国产网站| 亚洲一区二区视频在线| 东方av正在进入| 国产精品一区免费在线观看| 欧美不卡一二三| 国产极品一区二区| 在线观看国产精品网站| 国产盗摄女厕一区二区三区| 欧美成人国产一区二区| 亚洲男女在线观看| 亚洲成人7777| 欧美日韩在线播放一区| 97精品久久久午夜一区二区三区 | 丰满少妇高潮一区二区| 三级在线观看一区二区| 欧美日韩一区二区三区四区| 波多野结衣亚洲| 国产精品蜜臀av| 日韩在线视频免费看| 狠狠色狠狠色合久久伊人| 日韩精品一区二区三区在线播放 | 欧美一区二区三区的| av电影中文字幕| 亚洲最大成人网4388xx| 欧洲视频一区二区| 91蜜桃婷婷狠狠久久综合9色| 中文字幕在线观看一区二区| 97在线观看视频免费| 国产精品一区二区久久精品爱涩| www日韩大片| 国产极品视频在线观看| 国产乱人伦精品一区二区在线观看 | 欧美美女直播网站| 美女露出粉嫩尿囗让男人桶| 亚洲国产视频a| 欧美丰满少妇xxxxx高潮对白| 日本久久久久久久久久| 午夜国产精品影院在线观看| 91精品国产aⅴ一区二区| 亚洲黄色在线网站| 精彩视频一区二区三区| 国产农村妇女精品| √天堂中文官网8在线| www.欧美色图| 一区二区三区四区av| 7799精品视频| 亚洲成人网在线播放| 激情小说欧美图片| 国产精品国产自产拍在线| 色婷婷av一区二区三区gif| 下面一进一出好爽视频| 亚洲18女电影在线观看| 精品久久久久久久久久久久久久久| 成人激情五月天| 丁香婷婷综合五月| 一区二区三区国产精华| 欧美一区二区三区视频免费| 久久美女免费视频| 风流少妇一区二区| 亚洲综合久久久| 日韩欧美黄色影院| 国产又粗又长又黄的视频| 成人a区在线观看| 亚洲国产日韩a在线播放| 欧美大度的电影原声| 波多野结衣欲乱| 曰本三级日本三级日本三级| 日韩av成人高清| 国产欧美日韩亚州综合| 在线观看91视频| 久久久久亚洲av无码专区桃色| 国产一区二区三区高清播放| 亚洲女女做受ⅹxx高潮| 日韩一区二区电影网| 伊人久久久久久久久久久久久久| 91农村精品一区二区在线| 三级欧美在线一区| 国产精品三级久久久久三级| 欧美日韩久久不卡| 阿v天堂2014| 亚洲精品免费一二三区| 日韩一区二区三区电影在线观看 | 成人国产电影网| 午夜精品久久久久久久蜜桃app| 久久久亚洲精品石原莉奈| 日本电影欧美片| 精品少妇一区二区三区免费观| 成人黄动漫网站免费app| 日韩精品亚洲专区| 国产精品国产三级国产aⅴ无密码| 欧美肥大bbwbbw高潮| 免费成人深夜蜜桃视频| 熟妇高潮一区二区| 国产风韵犹存在线视精品| 天天操天天色综合| 国产精品高潮呻吟久久| 日韩欧美国产精品| 在线免费观看视频一区| 一级特黄曰皮片视频| 国产伦理在线观看| 国产成人精品网址| 日本亚洲免费观看| 亚洲精品综合在线| 久久精品日韩一区二区三区| 欧美精品欧美精品系列| 日韩在线观看视频一区二区| 日本黄色特级片|